Member Info for Soupdragon78

They're doing a good job whatever the reason, offer keeps being walked down.

why tomorrow?

Heres Boots selling CBD products over the counter. The same CBD is the basis for NFX testing the co-crystal applications.

https://www.boots.com/wellness/vitaminsandsupplements/vitamins-supplements-shop-by-ingredient/cannabidiol-cbd-oil

NFX have clearly stated they are not going into the Cannabis market.

But cannabinoids can, which is what the deal with Ebers was about.

Ask the company they will tell you, they have nothing to do with cannabis.

Just because I'm a nice guy ChrisRainy, here's me posting about NFX in Jan 2018 to save you the effort of looking back.

Soupdragon78
Posted in: NFX

Posts: 300
Price: 3.85
No Opinion

Interview now on Vox 31 Jan 2018 14:03
Under their Blog section. Goodman on at 17mins 55secs.

https://www.**********.co.uk/blogs/jubilee-metals-grp-jlp-upland-resources-upl-nuformix-nfx/

You might want to talk to Dan then, he has a completely different view to you.

Since I'm holding and have a weighted average of 2.2p its futile to try and suggest I'm talking the price down. I was posting here before you'd even heard of NFX.

Chrisrainy, medical cannaboids (the type NFX are looking at) is already legal in the UK and can be bought over the counter or on prescription.
NFX are not looking at cannabis, they are looking at hemp derivatives. They are two distinctly different things.

NFX work is nothing to do with tetrahydrocannabinols (THC), Dan has stated that in the past interviews. CBD (Cannabidiol) comes from the hemp plant and not marijuana plant.

First rule of code 1 conspiracy theory - Don't be a muppet.

Still being quoted 10.7p to sell 200k, so I guess whoever sold at 10.25 got mugged.

Wouldn't expect an RNS thats its been paid. As with the previous 500k, NFX only issued that it was agreed to be paid and due. Never issued a follow up RNS saying it had been paid as they don't have to do so.

RNS 30th May on NXP001

-- Trigger a final milestone payment of GBP2m from its Chinese licensing partner, Newsummit Biopharma, who have commenced product registration in China (Nuformix retains 10% royalty, with remaining milestone payments expected during June 2019)

From 2015

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-dexanabinol-for-advanced-cancer#undefined

Anthony, if you don’t even know what market a share is listed on then don’t expect people to listen to you. Stick to premium bonds.

People were identifying May as the time when NXP results would come through on the basis of Dans earlier interview. He stated approx 4-6 weeks after last dosing. Which puts us in that window now.

Fairly even trades today, sells above mid price. Currenty 6.7055p to sell hence show as buys.

Scary, the NXP001 results will validate the NFX business model should they be good. Helps set up everything else to follow.

Doesn’t actually matter who he is, or whether he is from Poznan or Portishead.

And if there is a TR1 from Higgins increasing his holding?

There’s a difference between Q1 and H1